Business Day|Costly Drug for Fatal Muscular Disease Wins FDA Approval – New York Times

New York TimesCredit Philip Scott Andrews for The New York Times. “We believe the Spinraza pricing decision is likely to invite a storm of criticism, up to and including presidential tweets,” Geoffrey C. Porges, an analyst for Leerink Partners, said in a note to … and more …read more From:: New York City News By […]

from WordPress http://ift.tt/2hBNwih
via IFTTT